<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355380</url>
  </required_header>
  <id_info>
    <org_study_id>15308</org_study_id>
    <secondary_id>VE1010PL</secondary_id>
    <nct_id>NCT01355380</nct_id>
  </id_info>
  <brief_title>Efficacy of Ventavis Used in Real-life Setting.</brief_title>
  <acronym>SPHERA</acronym>
  <official_title>The Efficacy of Inhaled Iloprost in Patients Treated Within the &quot;Pulmonary Arterial Hypertension Therapeutic Programme&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for
      treatment with Ventavis.

      Typical clinical measures and quality of life will be prospectively followed in 12 months
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2010</start_date>
  <completion_date type="Actual">September 22, 2016</completion_date>
  <primary_completion_date type="Actual">April 28, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of the exercise capacity as measured by 6-minutes walking distance</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of depression score over time</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of functional capacity as measured by WHO classification system</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pulmonary haemodynamics</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum level of natriuretic peptide B</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Quality of Life score</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac echo parameters</measure>
    <time_frame>3, 6, 9 and 12 months vs. baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Drug (incl. Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled iloprost (Ventavis, BAYQ6256)</intervention_name>
    <description>Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients prescribed Ventavis within the Pulmonary Arterial Hypertension Therapeutic
        Programme.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary arterial hypertension in WHO functional class III or IV

          -  Age 18+

          -  Patients newly treated with Ventavis or switched from sildenafil

        Exclusion Criteria:

          -  Retrospective documentation is not allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Inhaled iloprost</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

